Mood Disorders News

Treatment-resistant depression prevalence varied by sex, race and age, according to results of a cross-sectional study published in Journal of Clinical Psychiatry.

Sage Therapeutics Inc. and Biogen Inc. released 12-month data showing zuranolone was generally well-tolerated among adults with major depressive disorder.

Referrals from primary care providers to Pediatric Mental Health Care Access programs rose and involved more complex mental health concerns during the COVID-19 pandemic, according to study results.

Patients with major psychiatric disorders appeared to have higher rates of medical comorbidities linked to worse COVID-19 outcomes, according to results of a cross-sectional study published in JAMA Network Open.

Ketamine improved neurocognitive outcomes at 24 hours among patients with depression and suicidal ideation, according to study results published in Journal of Clinical Psychiatry.

The COVID-19 pandemic may have reduced overall mood and physical activity among study participants and increased their levels of self-reported stress, a speaker reported.

Two separate efforts, both involving training and education interventions for health care workers, show promise in reducing stigma and improving care for patients with mental health conditions, data show.

Adding lithium to usual care for veterans with major depression or bipolar disorders did not reduce incidence of suicide-related events, according to results of a randomized clinical trial published in JAMA Psychiatry.

The FDA has granted 510(k) clearance to neuroscience research and mental health treatment company Magstim for Horizon 3.0, its transcranial magnetic stimulation platform.

Randomized clinical trials of antidepressants often contain placebo run-in periods despite their apparent lack of benefits to outcome, according to results of a systematic review and meta-analysis published in JAMA Psychiatry.